Search Results for keywords:"Health and Human Services"

In January 2025, the Drug Enforcement Administration and the Department of Health and Human Services published new rules about expanding telemedicine practices. These rules were supposed to take effect on February 18, 2025, but have been delayed to March 21, 2025. This delay aligns with a Presidential order for a "Regulatory Freeze Pending Review," allowing more time for feedback on the rules. The rules allow certain medical professionals to prescribe medications via telemedicine, even without an initial in-person visit, under specific conditions. Public comments about this delay are encouraged, focusing on potential policy, legal, and factual issues.

The Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA) have issued a notice about two requests for proposals that were initially published on September 24, 2020. These proposals involve the reimportation of insulin and the personal importation of prescription drugs. The notice updates these proposals to include revised versions in the Federal Register. Responses to the proposals can be submitted via email and will be reviewed on a rolling basis.

The National Institute on Aging has announced a closed meeting scheduled for February 26, 2021, to review and evaluate grant applications. This meeting will not be open to the public as it may involve confidential information such as trade secrets or personal details about individuals associated with the applications. The event will be conducted via video meeting, and interested parties can contact Dr. Maurizio Grimaldi for more information. The announcement follows the provisions of the Federal Advisory Committee Act ensuring privacy and confidentiality.

The Administration for Children and Families within the U.S. Department of Health and Human Services has withdrawn a proposed rule concerning the Temporary Assistance for Needy Families (TANF) program. Originally proposed on October 2, 2023, the rule aimed to update TANF regulations, including defining "needy," clarifying allowable expenditures, and aligning holidays with Federal standards. After receiving over 7,000 comments, the department decided they need more public input and are focusing on other priorities, such as implementing the TANF provisions of the Fiscal Responsibility Act of 2023. Thus, the proposed rule has been officially withdrawn as of January 14, 2025.

The National Institute on Alcohol Abuse and Alcoholism is holding a closed meeting on March 5, 2025. The meeting will take place from 10:00 a.m. to 5:00 p.m. and will be conducted virtually. Participants will review and evaluate grant applications, which involve discussions that may reveal confidential information or personal details. This confidentiality aligns with federal rules to protect trade secrets and personal privacy.

The Food and Drug Administration (FDA) is inviting public comments on the proposed collection of specific information related to dietary supplement labeling. Under the Paperwork Reduction Act, federal agencies must publish notices for any information collection activities, allowing 60 days for public feedback. The proposal involves manufacturers, packers, or distributors of dietary supplements notifying the FDA about claims made on supplement labels. Comments can be submitted electronically or in writing by February 18, 2025.

The National Institutes of Health announced that the National Institute on Aging will hold a closed meeting on May 6, 2025. This meeting will involve a special emphasis panel focusing on developing therapies for Alzheimer's and related disorders using microphysiological systems. The meeting will be conducted virtually to review and evaluate contract proposals. Discussions will remain confidential to protect trade secrets and personal information.

The Centers for Medicare and Medicaid Services (CMS) has issued a notice acknowledging the application from The Joint Commission (TJC) for continued approval as a national accrediting body for hospitals involved in Medicare or Medicaid. The Joint Commission's current approval expires on July 15, 2025, and they are seeking renewal to ensure hospitals accredited by them meet or exceed Medicare standards. CMS invites public comments on TJC’s standards and survey processes by March 13, 2025, as part of the decision-making process to grant or deny the continuation of their approval.

The Food and Drug Administration (FDA) is seeking public comments on a proposed collection of information as part of its requirement for the Office of Management and Budget (OMB) review under the Paperwork Reduction Act of 1995. This initiative pertains to the application process for FDA approval to market new drugs, covering the submission of data and patent details as specified in FDA regulations. The FDA has developed specific forms to aid applicants and has made updates to the process to improve efficiency. Public comments on these proposals are welcomed by March 18, 2021.

The Food and Drug Administration (FDA) has released a draft guidance document titled "Evaluation of Sex-Specific and Gender-Specific Data in Medical Device Clinical Studies." This document aims to promote the inclusion and analysis of sex- and gender-specific data in medical device studies to ensure safety and effectiveness. Historically, females and nonbinary individuals have been underrepresented in clinical trials, leading to inadequate information about medical devices for these groups. The guidance encourages sponsors to incorporate diverse data in clinical studies and reporting, but it is currently not final and the public is invited to submit comments until April 7, 2025.